Literature DB >> 20617085

Involvement of selective alpha-2 adrenoreceptor in sympathetically maintained pain.

Chan Hong Park1, An Yong, Sang Ho Lee.   

Abstract

OBJECTIVE: Peripheral nerve injury often leads to neuropathic pain, which is characterized by burning pain, allodynia, and hyperalgesia. The role of the sympathetic nervous system in neuropathic pain is a complex and controversial issue. It is generally accepted that the alpha adrenoreceptor (AR) in sympathetic nerve system plays a significant role in the maintenance of pain. Among alpha adrenoreceptor, alpha-1 receptors play a major role in the sympathetic mediated pain. The primary goal of this study is to test the hypothesis that sympathetically maintained pain involves peripheral alpha-2 receptors in human.
METHODS: The study was a randomized, prospective, double-blinded, crossover study involving twenty patients. The treatments were : Yohimbine (30 mg mixed in 500 mL normal saline), and Phentolamine (1 mg/kg in 500 mL normal saline) in 500 mL normal saline at 70 mL/hr initially then titrated. The patients underwent infusions on three different appointments, at least one month apart. Thus, all patients received all 2 treatments. Pain measurement was by visual analogue scale, neuropathic pain questionnaire, and McGill pain questionnaire.
RESULTS: There were significant decreases in the visual analogue scale, neuropathic score, McGill pain score of yohimnine, and phentolamine.
CONCLUSION: We conclude that alpha-2 adrenoreceptor, along with alpha-2 adrenoreceptor, may be play role in sympathetically maintained pain in human.

Entities:  

Keywords:  Alpha-2 antagonist; Reflex sympathetic dystrophy; Yohimbine

Year:  2010        PMID: 20617085      PMCID: PMC2899027          DOI: 10.3340/jkns.2010.47.6.420

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  29 in total

Review 1.  Mechanisms of neuropathic pain.

Authors:  D Bridges; S W Thompson; A S Rice
Journal:  Br J Anaesth       Date:  2001-07       Impact factor: 9.166

2.  Yohimbine bioavailability in humans.

Authors:  S K Guthrie; M Hariharan; L J Grunhaus
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Yohimbine: a clinical review.

Authors:  S W Tam; M Worcel; M Wyllie
Journal:  Pharmacol Ther       Date:  2001-09       Impact factor: 12.310

4.  Ectopic adrenergic sensitivity in damaged peripheral nerve axons in the rat.

Authors:  E M Korenman; M Devor
Journal:  Exp Neurol       Date:  1981-04       Impact factor: 5.330

5.  alpha-1 and alpha-2 Adrenergic antagonists relieve thermal hyperalgesia in experimental mononeuropathy from chronic constriction injury.

Authors:  A H Hord; D D Denson; B Stowe; R M Haygood
Journal:  Anesth Analg       Date:  2001-06       Impact factor: 5.108

6.  Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury.

Authors:  J Sato; E R Perl
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

7.  Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin(1A) receptors.

Authors:  H E Shannon; E A Lutz
Journal:  Psychopharmacology (Berl)       Date:  2000-03       Impact factor: 4.530

8.  Sympathetic reactivity during a yohimbine challenge test in essential hypertension.

Authors:  D S Goldstein; E Grossman; S Listwak; C J Folio
Journal:  Hypertension       Date:  1991-11       Impact factor: 10.190

9.  Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats.

Authors:  Yoram Shir; Ze'ev Seltzer
Journal:  Pain       Date:  1991-06       Impact factor: 6.961

10.  Functional changes in dorsal root ganglion cells after chronic nerve constriction in the rat.

Authors:  Y Xie; J Zhang; M Petersen; R H LaMotte
Journal:  J Neurophysiol       Date:  1995-05       Impact factor: 2.714

View more
  1 in total

Review 1.  Janus molecule I: dichotomous effects of COMT in neuropathic vs nociceptive pain modalities.

Authors:  S K Segall; W Maixner; I Belfer; T Wiltshire; Z Seltzer; L Diatchenko
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-05       Impact factor: 4.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.